

## APA DSM-V Task Force Member Disclosure Report

Name : Wilson M Compton M.D.  
Job Title : Director  
Address : 6001 Executive Blvd Rm 5153  
Bethesda MD 20892-0001  
Role : **Member**  
Date : **5/2/2011**

### Task Force:

Task Force on DSM-V

### Biographical Sketch

Biographical Sketch:  
Member, DSM-V Task Force  
Director, Division of Epidemiology, Services and Prevention Research  
National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)  
Bethesda, MD

Wilson M. Compton, M.D., M.P.E. is Director of the Division of Epidemiology, Services and Prevention Research at the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. Prior to joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at the Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. He is a member of the Alpha Omega Alpha honor society as well as number professional organizations. He has been the principal or co-principal investigator of multiple federally funded grants focusing on the epidemiology of drug abuse, HIV prevention and co-occurring mental and drug use disorders. In these areas of research, Dr. Compton has authored over 100 articles and chapters, and several diagnostic interviews.

The table below represents the disclosure for Dr. Wilson M Compton M.D. of significant interests and affiliations for the three years prior to the DSM Task Force or a DSM Work Group member nomination and the period prior to public announcement of his/her appointment. The table also represents the reported disclosures of significant interests and affiliations for the past full calendar year and the current year to date for Dr. Wilson M Compton M.D..

Dr. Wilson M Compton M.D. has agreed that, from the time of approval through the publication of DSM-V, projected in 2013, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Relationship</b>	<b>Key(s)</b>
National Institute on Drug Abuse/ National Institute of Health	2005 - Present	Self	FTE or PTE
Agilent/ Amgen	2005 - 2007	Self	Stock
Baxter	2005 - 2007	Self	Stock
Boston Scientific	2005 - 2007	Self	Stock
Cardinal Health	2005 - 2007	Self	Stock
GlaxoSmithKline, Inc.	2005 - 2007	Self	Stock
Eli Lilly and Company	2005 - 2007	Self	Stock
Johnson & Johnson	2005 - 2007	Self	Stock
Merck & Co.	2005 - 2007	Self	Stock
Novartis Pharmaceuticals Corp.	2005 - 2007	Self	Stock
Omnicare	2005 - 2007	Self	Stock
Wyeth	2005 - 2007	Self	Stock
Zimmer Holdings	2005 - 2007	Self	Stock
E I DuPont	2005 - 2007	Self	Stock
Mediummune	2005 - 2007	Self	Stock
Shering AG	2005 - 2007	Self	Stock
Shering Plough	2005 - 2007	Self	Stock
Abbott Laboratories	2005 - Present	Self	Stock
Pfizer Inc.	2005 - Present	Self	Stock
General Electric	2005 - Present	Self	Stock
Praxair	2005 - Present	Self	Stock

The table below represents the reported disclosures of uncompensated leadership positions with Non-Profit or Advocacy Organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V for the three years prior to appointment and the current year to date for Wilson M Compton M.D..

<b>Non-Profit or Advocacy Organization</b>	<b>Year(s)</b>	<b>Relationship</b>	<b>Role</b>
None			